Author

Megan Couvillion

Observed names: Couvillion, Megan, Couvillion, Megan P., Megan P Couvillion, Megan P. Couvillion, Megan Poynot Couvillion

Institution: Alumis Inc. (United States)

Observed institution: Alumis Inc. (United States)

ORCID: 0000-0001-5766-5968

Observed ORCID: 0000-0001-5766-5968

OpenAlex ID: A5106910360

Improving Neck and Jawline Aesthetics With OnabotulinumtoxinA by Minimizing Platysma Muscle Contraction Effects: Efficacy and Safety Results in a Phase 3 Randomized, Placebo-Controlled Study

2024 · Sachin M Shridharani, Patricia Ogilvie, et al. · Aesthetic Surgery Journal · 23

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials

2025 · Neal Bhatia, James Del Rosso, et al. · JAMA Dermatology · 15

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study

2025 · Andrew Blauvelt, Petr Arenberger, et al. · Journal of the American Academy of Dermatology · 12

Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study

2025 · Todd Schlesinger, M. Shane Chapman, et al. · Journal of the American Academy of Dermatology · 9

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial

2025 · Amy McMichael, Mona Shahriari, et al. · JAMA Dermatology · 9

Allergic contact dermatitis from sorbitans in beer and bread.

2019 · Katharine Saussy, Megan Couvillion, et al. · PubMed · 4

54285 Evaluating the Safety and Efficacy of OnabotulinumtoxinA for the Treatment of Platysma Prominence: Results from a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

2024 · Sachin M. Shridharani, Megan Couvillion, et al. · Journal of the American Academy of Dermatology · 1

Red Light Photodynamic Therapy with 10% Aminolevulinic Acid Gel Showed Robust Efficacy for the Treatment of Superficial BCC in a Randomized, Vehicle-Controlled, Double-Blind, Multicenter Phase III Study

2025 · Todd Schlesinger, M. Shane Chapman, et al. · SKIN The Journal of Cutaneous Medicine

529 Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)

2025 · Kenneth Y Tsai, David K Glover, et al. · Journal for ImmunoTherapy of Cancer

A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy.

2025 · Joel L Cohen, John H Tu, et al. · PubMed

The history of botulinum toxin and its relationship to the skin

2022 · Megan Couvillion, Ashley W. Allen · Dermatological Reviews

Works count: 13

Citation count: 73

H-index: 5

I10-index: 3